Exploring Causes of Neurodegenerative Conditions with New Imaging Techniques
August 2024
MSD has embarked on a new collaboration with the Rosalind Franklin Institute (the Franklin) to investigate the causes of neurodegenerative conditions, like Parkinson’s Disease, using advanced imaging techniques.
At MSD we are dedicated to advancing our understanding of disease processes through partnerships. The Franklin develops new technologies to support life sciences and healthcare research, funded through the Engineering and Physical Sciences Research council, part of UK Research and Innovation.
This collaboration aims to uncover how malfunctioning of cell regulation processes are implicated in neurodegenerative conditions. By combining MSD’s expertise in drug discovery capabilities with Franklin’s Cryogenic tomography (CryoET) capabilities, we aim to increase the throughput of cellular samples and improve image resolution.
CryoET is a technique that scans the inside of cells to create detailed 3D images at the nanometre scale. This aims to advance our understanding of disease processes, which could have diagnostic benefits for both patients and our healthcare system.
Dr Sandra B. Gabelli, Executive Director and Head of Protein and Structural Chemistry at MSD Research Laboratories, explains that “Until now, structure-based drug design has relied on studying targets purified and removed from the cellular context. With cryoET, we want to explore the next frontier of drug discovery by visualising the drug targets in their native cellular context.”
The Franklin team have been developing this technology so it can be applied to visualise larger samples, such as whole cells or tissues of interest. This work has been carried out in collaboration with Thermo Fisher Scientific and is funded by Wellcome.
Dr Michael Grange, Group leader in Tomography at the Franklin emphasises the importance of collaborating with industry partners: “We are very excited that MSD is keen to be part of our journey. One of our core values is utility – we want to develop technologies that people want to use to achieve their own research goals, both academics and industry partners.”
CryoET is a relatively new technique with considerable barriers to entry. In efforts to expand its uses, this collaboration presents a valuable opportunity to combine Franklin’s technological advancements with MSD’s research expertise. Together, we aspire to gain deeper insights into cell regulation and associated conditions at the cellular level, paving the way for innovative approaches to tackle neurodegenerative diseases.
Dr Darren McKerrecher, Executive Director and Head of London Discovery Chemistry at MSD Research Laboratories, said:
“Enhanced cellular visualisation has the potential to enable a better understanding of underlying cell biology and help inform the pursuit of novel therapeutic mechanisms. We look forward to collaborating with the Rosalind Franklin Institute team and applying their capabilities and expertise in cryo electron tomography as we work to characterise new targets in drug discovery.”
For more information about this project, please contact corporateaffairsuk@msd.com.
GB-NON-09864 | August 2024